DRAFT GUIDANCE FOR INDUSTRY

CLINICAL DATA NEEDED TO SUPPORT THE LICENSURE OF TRIVALENT INACTIVATED INFLUENZA VACCINES

DOCKET NO. 2006-0083

REFERENCES

1. World Health Organization. WHO guidelines on nonclinical evaluation of vaccines. Annex 1. WHO Technical Report Series. 2005;927:31-63. www.who.int/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation/en/.

2. Lamb RA, Krug RM. *Orthomyxoviridae*: The Viruses and Their Replication. In: Fields Virology, Editors-in-Chief: Knipe DM and Howley PM. 4th Edition. Philadelphia, PA: Lippincott Williams and Wilkins, Publishers; 2001;1487-1531.

3. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. The Journal of Clinical Investigation. 2002;110:9-13.

4. Nakajima S, Nobusawa E, Nakajima K. Variation in response among individuals to antigenic sites on the HA protein of human influenza virus may be responsible for the emergence of drift strains in the human population. Virology. 2000;274:220-231.

5. Holmes EC, Ghedin E, Miller N, Taylor J, Bao Y, St. George K, Grenfell BT, Salzberg SL, Fraser CM, Lipman DJ, Taubenberger JK. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biology. 2005;3:1579-1589.

6. Barr IG, Komadina N, Hurt AC, Iannello P, Tomasov C, Shaw R, Durrant C, Sjogren H, Hampson AW. An influenza A(H3) reassortant was epidemic in Australia and New Zealand in 2003. Journal of Medical Virology. 2005;76:391-397.

7. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report. 2005;54(RR08):1-40.

8. Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report. 1997;46(RR-9):1-25.

9. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report. 2000;49(RR-3):1-38.

2006D-0083

BKG 1

10. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and Mortality Weekly Report. 2004;53(RR-6):1-40.

11. Centers for Disease Control and Prevention. Update: Influenza Vaccine Supply and Recommendations for Prioritization During the 2005--06 Influenza Season. MMWR Morbidity and Mortality Weekly Report. 2005;54(34);850:1-3.

12. Testimony of Julie L. Gerberding, M.D., M.P.H., Director, Centers for Disease Control and Prevention, on "Protecting the Public's Health: CDC Influenza Preparedness Efforts" before The Committee on Government Reform, U.S. House of Representatives, 2/12/2004. (Available at: http://www.cdc.gov/washington/testimony/In2122004200.htm).

13. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene, (Camb). 1972;70:767-777.

14. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus ADME. Haemagglutination-inhibiting antibody to influenza virus. Developmental Biology (Basel). 2003;115:63-73.

15. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. The European Agency for the Evaluation of Medicinal Products (EMEA), March 1997.

16. Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, Wolff M, Klimov A, Levandowski R, Lambert L. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20:1099-1105.